Game da C-CAR031

C-CAR031 magani ne mai ɗauke da sinadarin T-Cell (CAR-T) mai sarrafa kansa, wanda aka yi nazari a kansa don maganin HCC.

An gabatar da ci gaban binciken C-CAR031 a kan cutar kansar hanta (HCC) a taron shekara-shekara na American Society of Clinical Oncology (ASCO) da aka gudanar a Chicago a shekarar 2024.

Hanyoyi: Gwajin farko a cikin ɗan adam, wanda aka yi wa lakabin buɗewa, yana amfani da ingantaccen titration tare da ƙirar i3+3. GPC3+ masu ci gaba na HCC waɗanda suka gaza maganin tsarin ≥ 1 sun sami jiko ɗaya na iv na C-CAR031 bayan an yi amfani da lymphostasis na yau da kullun. Babban maƙasudin ƙarshen sune aminci da jurewa, wasu sun haɗa da pharmacokinetics da ingancin farko. An kimanta abubuwan da suka faru marasa kyau (AEs) ta hanyar CTCAE 5.0, kuma an tantance cutar cytokine release syndrome (CRS) / immunoeffector neurotoxicity syndrome (ICANS) bisa ga ka'idojin ASTCT 2019. Mai bincike ya tantance martanin manufa ta hanyar RECIST 1.1.

Sakamako: Ya zuwa ranar 5 ga Janairu, 2024, jimillar maki 24 sun sami jiko na C-CAR031 a matakan allurai 4 (DLs). Duk maki suna da matakin BCLC C HCC, 83.3% (20/24) suna da metastasis na waje na hanta. Matsakaicin adadin layukan magani na baya shine 3.5 (tsakanin 1-6), maki 23 (95.8%) da aka karɓi ICIs (masu hana garkuwar jiki) da TKIs (masu hana tyrosine kinase). An kimanta duk maki don aminci. Babu guba mai iyakance allurai kuma an lura da ICANS. An lura da CRS a maki 22 (91.7%) tare da maki 1 (4.2%) na matakin (G) 3 CRS. Mafi yawan ≥G3 AEs sune lymphocytopenia (100%), neutropenia (70.8%), thrombocytopenia (37.5%) da haɓakar transaminase (16.7%). Mutum ɗaya (4.2%) yana da G4 myelosuppression kuma 1 pt (4.2%) yana da G3 interstitial pneumonia a DL4 wanda G3 CRS ya haifar. Duk AEs an iya mayar da su baya. An kimanta maki 22 don inganci. An lura da raguwar ƙari a cikin maki 90.9%, ba kawai a cikin raunukan ciki ba har ma da waɗanda ke waje da hanta tare da matsakaicin raguwar kashi 44.0% (kewayon, 3.4%-94.4%). Yawan rage cutar shine 90.9% kuma ƙimar amsawar manufa (ORR) shine 50.0% ga maki na duk DLs. A cikin DL4, ORR shine 57.1%.

Kammalawa: Binciken ya nuna ingantaccen tsarin aminci da kuma ƙarfafa aikin hana ƙari na C-CAR031 a cikin marasa lafiya da suka kamu da cutar HCC da aka yi wa magani sosai.

A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.

Lambar Waya: 4008803716

Email：myimmnet@163.com

Nassoshi

1.https://www.prnewswire.com/news-releases/abelzeta-announces-clinical-data-showing-preliminary-anti-tumor-activity-for-c-car031-an-armored-autologous-gpc3-car-t-in-patients-with-advanced-hepatocellular-carcinoma-at-asco-annual-meeting-2024-302162941.html

2.https://www.abelzeta.com/abelzeta-announces-abstract-for-c-car031-accepted-for-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/

3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019

4.ASCO-2024-IR-Presentation.pdf (astrazeneca.com)